ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
ImmunityBio (NASDAQ:IBRX) CEO Richard Adcock used a presentation at the Citizens Life Sciences Conference to outline the company's commercial progress with its lead product ANKTIVA and to highlight multiple upcoming regulatory and clinical milestones across bladder cancer, lung cancer, and earlier-stage pipeline programs. Company strategy and platform focus Adcock said ImmunityBio's work reflects founder Dr. Patrick Soon-Shiong's long-standing view that combination therapy is required to “beat cancer,” a strategy he said the company began pursuing in 2010. Adcock described ImmunityBio's development engine as three platform technologies: Fusion proteins , led by ANKTIVA DNA vaccine vectors , which he characterized as second-generation adenoviral vectors capable of delivering large payloads Cellular therapies , including off-the-shelf CAR-NK programs ? Data Storage to Data Intelligence: Everpure's Big AI Era Rebrand Biotech Breakouts: 3 Stocks With Massive Upside Potentia
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer [Yahoo! Finance]Yahoo! Finance
- ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion [Seeking Alpha]Seeking Alpha
- NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.MarketBeat
- ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/26/26 - Form 4
- 2/25/26 - Form SCHEDULE
- 2/24/26 - Form 4
- IBRX's page on the SEC website